Merck Sharpe and Dohme and Sanofi Pasteur begin new vaccine trial

Posted on 26/04/2011 in Pharmaceutical Company Product News

Merck Sharpe and Dohme and its partner Sanofi Pasteur have commenced a clinical study of a new vaccine designed to treat a range of diseases among children.

The companies have begun a phase III study of the hexavalent combination vaccine that will test the safety and immunogenicity of the drug when administered concomitantly with Prevnar 13 and Rotateq.

Read more….

Speak Your Mind